Palisade Bio appoints Mitchell Jones as CMO; grants inducement options and RSUs

PALISADE BIO, INC.

Mitchell Jones, M.D., Ph.D., appointed Chief Medical Officer effective Sept 5, 2023.
Herbert Slade ceased as CMO same date, will continue as consultant.
Inducement grant: 75,000 options at $0.6897/share, 54,700 RSUs; vest over 3 years.
Jones previously VP at Chemomab (CMMB), Finch Therapeutics (FNCH), Biora (BIOR); IBD expertise.
Employment: base salary $415,000, target bonus 40%, severance provisions.

item 1.01 item 5.02 item 3.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mitchell Jones

Chief Medical Officer

PALI · PALISADE BIO, INC.

Effective: 2023-09-05
Filed: September 11, 2023, 7:59 PM ET

Mitchell Jones, M.D., Ph.D. (“Dr. Jones”) has been appointed Chief Medical Officer effective September 5, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mitchell Jones was appointed as Chief Medical Officer at PALISADE BIO, INC..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Mitchell Jones, M.D., Ph.D. (“Dr. Jones”) has been appointed Chief Medical Officer effective September 5, 2023

View on SEC.gov

PALISADE BIO, INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-032278

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.